The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1424
Breo Ellipta: An Inhaled Fluticasone/Vilanterol Combination for COPD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved an inhaled fixed-dose combination (Breo Ellipta – GSK/Theravance) of the corticosteroid fluticasone furoate and the long-acting beta2-adrenergic agonist (LABA) vilanterol trifenatate for once-daily treatment of chronic obstructive pulmonary disease (COPD).

This is the first approved indication for vilanterol. Fluticasone furoate is also approved as a nasal spray for treatment of allergic rhinitis. Fluticasone propionate is available alone for treatment of asthma and in combination with salmeterol for treatment of COPD and asthma. Breo Ellipta has not been approved for use in asthma.

MAINTENANCE TREATMENT OF COPD — For patients with moderate to severe airflow obstruction and chronic symptoms, regular treatment with an inhaled long-acting bronchodilator (a LABA or an anticholinergic) can relieve symptoms, improve lung function, decrease the frequency of exacerbations, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Breo Ellipta: An Inhaled Fluticasone Vilanterol Combination for COPD
Article code: 1424a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian